AVIR · Healthcare · $403M
After-hours $5.01-3.84%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 463 Biotechnology peers
“C-BEYOND에서 베무루자스비르의 완치율은 93.9%로 기존 표준치료의 94.8%와 통계적으로 뒤지지 않았어요.”
In the company's words · 2026 2분기 earnings call